The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.

In an interview with Dr. Phil, the health secretary offered false information about vaccine oversight and revealed a lack of ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.

Pakistan’s pharmaceutical embargo on Indian imports thus stands as both a calculated gamble and a potential blueprint for ...

Kennedy has focused his healthcare crusade on his contention that American healthcare prioritizes treating chronic illnesses ...

The FDA and other HHS agencies of interest to the pharma sphere have seen President Donald Trump’s first 100 days as he ...

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

Today marks 100 days since President Donald Trump took office — a period for the health care world that’s been distinguished ...

Among other things, Makary breaks some news here by stating, for the first time, that there will be no significant ...

While Vaxart can proceed with its study, fellow COVID-19 vaccine developers GeoVax and Novavax continue to be hamstrung by ...